EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY‐DIAGNOSED MULTIPLE MYELOMA

The duration of response to treatment is a major prognostic factor and early relapse (ER) strongly predicts inferior survival in multiple myeloma (MM) patients. But the definitions ER MM varied from study study. In this study, we aimed identify best timepoint which integrated with initial traditional risk features formulate novel classification incorporating both static dynamic risk. was based on National Longitudinal Cohort Hematological Diseases China (NCT04645199) total 629 patients diagnosed NDMM were included We first summarized all studies about published date found that within 18 months or 12 SCT mostly used define PD many studies. Our findings indicate ER18 could effectively balance bias for without ASCT, as well fulfill requirements predictor. population (114/587; 19.4%) presented more aggressive biologic compared reference cohort (P < 0.001), significant short median overall (OS) 28.9 months. also described specific transitions profile distribution our then constructed mixed-risk pattern four populations distinct outcomes 0.001). A 367 (67.0%) at least one high-risk feature: those ISS III stage, elevated LDH, HRCAs classified baseline (BHR) group; 86 (23.4%) experienced further defined mixed (MHR) population, remaining (SHR). Within BHR features, event (ER18) occurred 21(11.6%) patients, functional (FHR). As expected, MHR had worst OS 25.9 Of note, FHR similar SHR (OS: not reached vs. 71.4 months; P = 0.235; Figure 3B), supporting importance suggesting lack durable exert an adverse impact prognosis variables. Moreover, confirmed refined predictive accuracy Revised International Staging System stage (R-ISS). Encore Abstract - previously submitted EHA 2023 Keywords: Diagnostic Prognostic Biomarkers, Multiple Myeloma, Risk Models No conflicts interests pertinent abstract.